Thermo Fisher Scientific and Mayo Clinic today announced a new collaboration that will take place near the respected health provider’s main Rochester, Minn. campus.
The partnership will focus on accelerating clinical validation and commercialization of certain next-generation sequencing (NGS), mass spectrometry and immunology diagnostic tools. Work will occur at the Advanced Diagnostics Laboratory at the 90,000-square-foot One Discovery Square that opened off Mayo Clinic’s Rochester campus in 2019.
“By pairing cutting-edge, innovative technologies with world-class clinical and diagnostic testing knowledge, this collaboration will ensure that the promising innovations are both clinically relevant and accessible globally,” said Dr. William Morice II, chair of Mayo Clinic’s Department of Laboratory Medicine and Pathology and president of Mayo Clinic Laboratories.
The Mayo Clinic and Thermo Fisher teams are in the process of identifying which technologies they will focus on first.
“We are excited to join forces with Mayo Clinic to accelerate access to precise and affordable diagnostics for patients across the globe,” said Gianluca Pettiti, SVP and president of Specialty Diagnostics at Thermo Fisher. “The collaborative effort will leverage NGS, mass spectrometry and immunology technologies to advance hematology, oncology, allergy and autoimmunity diagnostics.”
The collaboration is but the latest partnership to spring out of the 20-year Destination Medical Center project in Minnesota, in which $585 million in state and local government infrastructure funds are expected to leverage about $5 billion of private investment in Rochester.